Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Taxes (2017 - 2019)

CytomX Therapeutics' Current Taxes history spans 3 years, with the latest figure at $13.4 million for Q1 2019.

  • For Q1 2019, Current Taxes rose 1192.17% year-over-year to $13.4 million; the TTM value through Mar 2019 reached $13.4 million, up 1192.17%, while the annual FY2018 figure was $13.3 million, 1333800.0% up from the prior year.
  • Current Taxes reached $13.4 million in Q1 2019 per CTMX's latest filing, roughly flat from $13.3 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $13.4 million in Q1 2019 to a low of $1000.0 in Q4 2017.
  • Average Current Taxes over 3 years is $5.9 million, with a median of $3.8 million recorded in 2018.
  • Peak YoY movement for Current Taxes: surged 1333800.0% in 2018, then surged 1192.17% in 2019.
  • A 3-year view of Current Taxes shows it stood at $1000.0 in 2017, then soared by 1333800.0% to $13.3 million in 2018, then rose by 0.26% to $13.4 million in 2019.
  • Per Business Quant, the three most recent readings for CTMX's Current Taxes are $13.4 million (Q1 2019), $13.3 million (Q4 2018), and $5.0 million (Q3 2018).